Galera Therapeutics, Inc. (NasdaqGM:GRTX) has engaged Stifel, Nicolaus & Company, Inc. to assist in reviewing strategic alternatives for the Company and its portfolio of dismutase mimetics with the goal of maximizing value for its shareholders. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. If the Company is unable to undertake any strategic alternative, it may be required to cease operations altogether.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 USD | +1.16% | -4.24% | +22.70% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Mar. 28 | Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+22.70% | 9.41M | |
+9.67% | 106B | |
+0.95% | 104B | |
+6.72% | 23.25B | |
-13.52% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-11.00% | 16.99B | |
+7.96% | 14.26B | |
+39.56% | 12.76B |
- Stock Market
- Equities
- GRTX Stock
- News Galera Therapeutics, Inc.
- Galera Therapeutics Announces Review of Strategic Alternatives